In the present study, the GSTM5-reduced GSH level inhibited the proliferation of bladder cancer cells (Figure 4C) but did not affect sensitivity to cisplatin and mitomycin C (Figure 8). Here, GSTM5 is linked to urinary bladder carcinoma.